Role of Lipid Phosphatases in Cholesterol and Triglyceride Synthesis
脂质磷酸酶在胆固醇和甘油三酯合成中的作用
基本信息
- 批准号:7527245
- 负责人:
- 金额:$ 6.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-08-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:1,2-diacylglycerolAddressAdipose tissueAmplifiersAnabolismBasic ScienceBehaviorBindingBiochemicalBiochemistryBiologicalBiological AssayBody fatCaloriesCardiovascular DiseasesCardiovascular systemCause of DeathCell NucleusCell modelCellsCerebrovascular DisordersCholesterolCholesterol Synthesis InhibitionClassClinical ManagementConditionCountryDataDepositionDesire for foodDetergentsDevelopmentDietDiet ModificationDietary CholesterolDiglyceridesDiphosphatesDiseaseDrug Delivery SystemsEffectivenessElevationEndoplasmic ReticulumEnzymatic BiochemistryEnzymesEquilibriumExcretory functionExhibitsFarnesolFundingGene FamilyGenesGeneticGlycerophospholipidsGoalsIn VitroInterventionIntracellular MembranesIsoprenoid PhosphatesKnowledgeLecithinLipidsLipoproteinsLocalizedMalignant NeoplasmsMediatingMembraneMembrane LipidsMembrane ProteinsMetabolicMetabolic DiseasesMetabolismMolecularMolecular and Cellular BiologyMono-SMorbidity - disease rateNuclear EnvelopeObesityOutputPathway interactionsPeripheralPharmaceutical PreparationsPhosphatidate PhosphatasePhosphatidic AcidPhospholipidsPhosphoric Monoester HydrolasesPhysical activityPlayPositioning AttributePrevalenceProcessProtein IsoformsProtein IsoprenylationProteinsPublic HealthRangeRegulationResearchResearch Project GrantsRoleSignal TransductionSourceSpecific qualifier valueSphingolipidsSterolsSystemTechniquesTestingTriglyceridesViral VectorWorkYeastsabsorptionbasecardiovascular risk factorenergy balanceenzyme activityenzyme pathwaygeranylgeraniolhuman diseasehypercholesterolemiaimprovedinorganic phosphateinsightisoprenoidlipid metabolismlipinemembermembrane modelmevalonatemortalitymouse modelnovelobesity managementobesity treatmentphosphate esterpreferenceprogramsprospectivesuccesstherapeutic targettherapy development
项目摘要
DESCRIPTION (provided by applicant): Cardiovascular and cerebrovascular diseases are the leading causes of death worldwide. Obesity, elevations in circulating levels of cholesterol and triglycerides and alterations in the composition of circulating lipoproteins are major risk factors for cardiovascular and cerebrovascular disease. Obesity is a disorder of energy balance. When energy input exceeds energy output most of the excess calories consumed are converted to triglycerides and stored in adipose tissue. Similarly, increases in circulating cholesterol leading to cholesterol deposition in the vasculature occur when the balance between de novo synthesis of cholesterol and provision of cholesterol from dietary sources exceeds normal cholesterol requirements and capacity to eliminate this essential sterol. Clinical management of obesity and its complications including hypercholesterolemia presently focuses on modifications of diet, physical activity and behavior. Because these strategies are of limited effectiveness, the prevalence of obesity continues to increase. Pharmacological inhibition of cholesterol synthesis is the primary and presently most effective strategy for the clinical management of hypercholesterolemia. Although to date efforts to develop pharmacological strategies for treatment of obesity focusing on appetite suppression and interference with lipid absorption have met with moderate success, recent advances using mouse models suggest that inhibition of triglyceride synthesis may be a viable and effective treatment strategy. Identification of components of the pathways responsible for synthesis of triglycerides and cholesterol and development of a complete understanding of how these processes are regulated is therefore critical for the development of new or improved agents for treatment of obesity and hypercholesterolemia. Because of their pivotal position in cellular metabolism, the pathways responsible for the de novo synthesis of cholesterol and triglycerides have been intensively studied but significant gaps in our knowledge remain. Two classes of lipid phosphate esters, polyisoprenoid diphosphates and phosphatidic acid are critical intermediates in the synthesis of cholesterol and triglyceride but enzymes that dephosphorylate these intermediates have only recently been identified. The overall goal of this research is to address these gaps in our knowledge by investigating the regulation and function of two newly identified lipid phosphatases that play central roles in the synthesis of isoprenoids, sterols and triglycerides. Our research uses techniques of biochemistry, cell and molecular biology to study the regulation and function of these enzymes in vitro and in biomedically relevant model cell systems. In the first aim we will use these approaches to test the hypothesis that an integral membrane enzyme termed polyisoprenoid diphosphate phosphatase is a regulator of cholesterol synthesis and protein isoprenylation. In the second aim of the proposal we will test the hypothesis that activity of a phosphatidic acid phosphatase enzyme that catalyses a critical step in triglyceride synthesis is regulated by a novel membrane targeting motif. PUBLIC HEALTH RELEVANCE: Obesity and elevated cholesterol levels are major risk factors for Cardiovascular and Cerebrovascular disease which are the leading causes of death in this country. Obesity is a disorder of energy balance. When energy input exceeds energy output most of the excess calories consumed are converted to triglycerides and stored as body fat. Similarly, increases in circulating cholesterol occur when the balance between cholesterol synthesis and provision of cholesterol from dietary sources exceeds normal cholesterol requirements and cholesterol excretion. In this research project we will test specific hypotheses about the regulation and function of newly identified enzymes that play central roles in the synthesis and metabolism of fat and cholesterol. Completion of our work will provide new insights into how synthesis of these lipids is regulated, how this process may be altered in disease and the feasibility of targeting these processes to provide novel therapies for obesity and cardiovascular disease.
描述(由申请人提供):心脑血管疾病是全世界死亡的主要原因。肥胖、循环胆固醇和甘油三酯水平升高以及循环脂蛋白组成的改变是心脑血管疾病的主要危险因素。肥胖是一种能量平衡紊乱。当能量输入超过能量输出时,消耗的大部分多余热量会转化为甘油三酯并储存在脂肪组织中。类似地,当胆固醇从头合成与膳食来源提供的胆固醇之间的平衡超过正常胆固醇需求和消除这种必需甾醇的能力时,循环胆固醇增加,导致胆固醇沉积在脉管系统中。肥胖及其并发症(包括高胆固醇血症)的临床治疗目前侧重于饮食、体力活动和行为的改变。由于这些策略的效果有限,肥胖的患病率持续增加。胆固醇合成的药物抑制是高胆固醇血症临床治疗的主要且目前最有效的策略。尽管迄今为止,开发治疗肥胖症的药理学策略(重点是抑制食欲和干扰脂质吸收)已取得一定成功,但使用小鼠模型的最新进展表明,抑制甘油三酯合成可能是一种可行且有效的治疗策略。因此,鉴定负责合成甘油三酯和胆固醇的途径的成分并全面了解如何调节这些过程对于开发用于治疗肥胖和高胆固醇血症的新的或改进的药物至关重要。由于它们在细胞代谢中的关键地位,负责胆固醇和甘油三酯从头合成的途径已被深入研究,但我们的知识仍然存在重大差距。两类脂质磷酸酯、聚异戊二烯二磷酸酯和磷脂酸是胆固醇和甘油三酯合成中的关键中间体,但使这些中间体去磷酸化的酶直到最近才被发现。这项研究的总体目标是通过研究两种新发现的脂质磷酸酶的调节和功能来弥补我们的知识空白,这两种酶在类异戊二烯、甾醇和甘油三酯的合成中发挥着核心作用。我们的研究利用生物化学、细胞和分子生物学技术来研究这些酶在体外和生物医学相关模型细胞系统中的调节和功能。在第一个目标中,我们将使用这些方法来测试以下假设:称为聚异戊二烯二磷酸磷酸酶的整合膜酶是胆固醇合成和蛋白质异戊二烯化的调节剂。在该提案的第二个目标中,我们将测试以下假设:催化甘油三酯合成关键步骤的磷脂酸磷酸酶的活性受到新型膜靶向基序的调节。公共卫生相关性:肥胖和胆固醇水平升高是心脑血管疾病的主要危险因素,而心脑血管疾病是该国的主要原因。肥胖是一种能量平衡紊乱。当能量输入超过能量输出时,消耗的大部分多余热量会转化为甘油三酯并作为体内脂肪储存。同样,当胆固醇合成与膳食来源提供的胆固醇之间的平衡超过正常胆固醇需求和胆固醇排泄时,循环胆固醇就会增加。在这个研究项目中,我们将测试有关新发现的酶的调节和功能的具体假设,这些酶在脂肪和胆固醇的合成和代谢中发挥着核心作用。我们工作的完成将为了解这些脂质的合成如何受到调节、这一过程在疾病中如何改变以及针对这些过程为肥胖和心血管疾病提供新疗法的可行性提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW J MORRIS其他文献
ANDREW J MORRIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW J MORRIS', 18)}}的其他基金
Lysophosphatidic Acid and Cardiovascular Disease Risk
溶血磷脂酸与心血管疾病风险
- 批准号:
10614416 - 财政年份:2021
- 资助金额:
$ 6.76万 - 项目类别:
Lysophosphatidic Acid and Cardiovascular Disease Risk
溶血磷脂酸与心血管疾病风险
- 批准号:
10386914 - 财政年份:2021
- 资助金额:
$ 6.76万 - 项目类别:
Lysophosphatidic Acid and Cardiovascular Disease Risk
溶血磷脂酸与心血管疾病风险
- 批准号:
10258072 - 财政年份:2021
- 资助金额:
$ 6.76万 - 项目类别:
Serum Amyloid as a Critical mediator between inflammation and thrombosis
血清淀粉样蛋白是炎症和血栓形成之间的关键介质
- 批准号:
10807568 - 财政年份:2020
- 资助金额:
$ 6.76万 - 项目类别:
ShEEP Request For Gas Chromatograph Mass Spectrometer
ShEEP 请求气相色谱质谱仪
- 批准号:
9795013 - 财政年份:2019
- 资助金额:
$ 6.76万 - 项目类别:
Lipid phosphate phosphatase 3 as a novel atherosclerosis suppressor
脂质磷酸磷酸酶 3 作为新型动脉粥样硬化抑制剂
- 批准号:
8888525 - 财政年份:2015
- 资助金额:
$ 6.76万 - 项目类别:
Association of a common variant of the PPAP2B gene with cardiovascular disease.
PPAP2B 基因的常见变异与心血管疾病的关联。
- 批准号:
8774196 - 财政年份:2013
- 资助金额:
$ 6.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 6.76万 - 项目类别:
Research Grant